Working from home or on site, all the pieces of the ANS Biotech puzzle stay strongly united and mobilized to pursue to proudly serve you.
We all need good news... Because good news is welcome, both in good times and bad, we are pleased to announce the launch of a new version of our model of Oxaliplatin-induced cold allodynia.
In the current global health context, ANS Biotech is mobilizing and adapting so as not to stop its support in the services for its Customers. We remain available online and fully mobilized for your projects.
We are pleased to announce that ANS Biotech is now an official registered vendor on the Science Exchange platform! Visit our Provider profile (https://www.scienceexchange.com/labs/ans-biotech) and easily start a collaboration with us!
The arrival of the SNI model strengthens the already available offer of services in the field of traumatic neuropathic pain.
ANS Biotech announces a collaborative agreement with Oroxcell for the bioanalyses of sampled fluids & tissues !
ANS Biotech will attend 2019 BIO International Convention, Philadelphia, PA, USA. Join us in Philadelphia, PA, June 3-6, 2019 as more than 16,000 attendees.
On Tuesday the 4th of December 2018, the local newspaper “La Montagne”, had an interview with the CEO, François Caussade. READ THE ARTICLE
ANS Biotech attended 17th World Congress on Pain in Boston, MA (September 12-16, 2018). ANS Biotech presented a poster titled: Comparison of the antinociceptive and antipruritic effects of kappa opioid receptor agonists on models of itch and pain.